TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind Trial in Ventilated ICU Patients Comparing Treatment With an Alpha2 Agonist Versus a Gamma Aminobutyric Acid (GABA)-Agonist to Determine Delirium Rates, Efficacy of Sedation, Analgesia and Discharge Cognitive Status
Brief Summary: Delirium has recently been shown as a predictor of death, increased cost, and longer length of stay in ventilated patients. Sedative and analgesic medications relieve anxiety and pain, but may contribute to patients' transitioning into delirium. It is possible that modifying the paradigm for sedation using novel therapies targeted at different receptors, such as dexmedetomidine targeting alpha2 receptors and sparing the GABA receptors, could provide efficacious sedation yet reduce the development, duration, and severity of acute brain dysfunction (delirium).


Options:
A: Arm Label: Early PT OT; Type: EXPERIMENTAL; Interventions: Procedure: early PT OT | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: early PT OT; Assigned to Arm(s): Early PT OT
B: Arm Label: Haloperidol 1mg/q8h; Type: EXPERIMENTAL; Interventions: Drug: Haloperidol 1 mg/q8h | Arm Label: Haloperidol 2mg/q8h; Type: EXPERIMENTAL; Interventions: Drug: Haloperidol 2 mg/q8h | Arm Label: Sodium chloride 0.9%; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Haloperidol 1 mg/q8h; Assigned to Arm(s): Haloperidol 1mg/q8h | Intervention Type: DRUG; Name: Haloperidol 2 mg/q8h; Assigned to Arm(s): Haloperidol 2mg/q8h | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sodium chloride 0.9%
C: Arm Label: Dexmedetomidine group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: Lorazepam group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lorazepam | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine group | Intervention Type: DRUG; Name: Lorazepam; Assigned to Arm(s): Lorazepam group
D: Arm Label: delirious patients; Type: N/A; Interventions: N/A | Arm Label: non-delirious patients; Type: N/A; Interventions: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind Trial in Ventilated ICU Patients Comparing Treatment With an Alpha2 Agonist Versus a Gamma Aminobutyric Acid (GABA)-Agonist to Determine Delirium Rates, Efficacy of Sedation, Analgesia and Discharge Cognitive Status
Brief Summary: Delirium has recently been shown as a predictor of death, increased cost, and longer length of stay in ventilated patients. Sedative and analgesic medications relieve anxiety and pain, but may contribute to patients' transitioning into delirium. It is possible that modifying the paradigm for sedation using novel therapies targeted at different receptors, such as dexmedetomidine targeting alpha2 receptors and sparing the GABA receptors, could provide efficacious sedation yet reduce the development, duration, and severity of acute brain dysfunction (delirium).


Options:
A: Intervention Type: PROCEDURE; Name: SAT: Spontaneous Awakening Trial; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: SBT: Spontaneous Breathing Trial; Assigned to Arm(s): N/A
B: Intervention Type: PROCEDURE; Name: Daily interruption of sedation versus sedation algorithm; Assigned to Arm(s): N/A
C: Intervention Type: PROCEDURE; Name: Sedation management strategy; Assigned to Arm(s): N/A
D: Arm Label: Dexmedetomidine group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: Lorazepam group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lorazepam | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine group | Intervention Type: DRUG; Name: Lorazepam; Assigned to Arm(s): Lorazepam group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind Trial in Ventilated ICU Patients Comparing Treatment With an Alpha2 Agonist Versus a Gamma Aminobutyric Acid (GABA)-Agonist to Determine Delirium Rates, Efficacy of Sedation, Analgesia and Discharge Cognitive Status
Brief Summary: Delirium has recently been shown as a predictor of death, increased cost, and longer length of stay in ventilated patients. Sedative and analgesic medications relieve anxiety and pain, but may contribute to patients' transitioning into delirium. It is possible that modifying the paradigm for sedation using novel therapies targeted at different receptors, such as dexmedetomidine targeting alpha2 receptors and sparing the GABA receptors, could provide efficacious sedation yet reduce the development, duration, and severity of acute brain dysfunction (delirium).


Options:
A: Arm Label: Dexmedetomidine group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: Lorazepam group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lorazepam | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine group | Intervention Type: DRUG; Name: Lorazepam; Assigned to Arm(s): Lorazepam group
B: Intervention Type: PROCEDURE; Name: SAT: Spontaneous Awakening Trial; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: SBT: Spontaneous Breathing Trial; Assigned to Arm(s): N/A
C: Arm Label: Midazolam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam | Arm Label: Dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: Dexmedetomidine | Intervention Type: DRUG; Name: Midazolam; Assigned to Arm(s): Midazolam | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Dexmedetomidine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Propofol | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Propofol; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Brief Strategic Family Therapy for Adolescent Drug Abusers
Brief Summary: The purpose of this study is to compare Brief Strategic Family Therapy (BSFT) for Adolescent Drug Abusers to treatment as usual (TAU).

An additional follow up assessment, funded by an American Recovery \& Reinvestment Act (ARRA) grant, was completed 5 years post randomization in order to examine the long term effects of outpatient treatments for illicit drug using adolescents.


Options:
A: Arm Label: Family Spirit Intervention; Type: EXPERIMENTAL; Interventions: Procedure: Family Spirit Intervention | Arm Label: Optimized Standard Care Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Family Spirit Intervention; Assigned to Arm(s): Family Spirit Intervention
B: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise and counseling (for smoking cessation and physical activity) | Arm Label: physical activity program; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise and counseling (for smoking cessation and physical activity) | Intervention Type: BEHAVIORAL; Name: Exercise and counseling (for smoking cessation and physical activity); Assigned to Arm(s): Control, physical activity program
C: Arm Label: Traditional Contingency Management; Type: EXPERIMENTAL; Interventions: Behavioral: Traditional Contingency Management | Arm Label: Early Enhanced Contingency Management; Type: EXPERIMENTAL; Interventions: Behavioral: Early Enhanced Contingency Management | Arm Label: Standard Treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Treatment | Intervention Type: BEHAVIORAL; Name: Standard Treatment; Assigned to Arm(s): Standard Treatment | Intervention Type: BEHAVIORAL; Name: Traditional Contingency Management; Assigned to Arm(s): Traditional Contingency Management | Intervention Type: BEHAVIORAL; Name: Early Enhanced Contingency Management; Assigned to Arm(s): Early Enhanced Contingency Management
D: Arm Label: Brief Strategic Family Therapy (BSFT); Type: EXPERIMENTAL; Interventions: Behavioral: Brief Strategic Family Therapy (BSFT) | Arm Label: Treatment as Usual (TAU); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as Usual | Intervention Type: BEHAVIORAL; Name: Brief Strategic Family Therapy (BSFT); Assigned to Arm(s): Brief Strategic Family Therapy (BSFT) | Intervention Type: BEHAVIORAL; Name: Treatment as Usual; Assigned to Arm(s): Treatment as Usual (TAU)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Peer Related School Interventions in Autism
Brief Summary: This study will determine whether peer interaction training interventions are effective in enhancing the social relationships of children with autism.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Social skills training targeting children with autism | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Social skills training of peers without autism | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Combination treatment of social skills/education about autism | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual training | Intervention Type: BEHAVIORAL; Name: Social skills training targeting children with autism; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Social skills training of peers without autism; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Combination treatment of social skills/education about autism; Assigned to Arm(s): 3 | Intervention Type: BEHAVIORAL; Name: Usual training; Assigned to Arm(s): 4
B: Intervention Type: BEHAVIORAL; Name: Caregiver joint attention intervention; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Early intervention blending several tx approaches, w/ focus | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Early intervention blending several treatment approaches | Intervention Type: BEHAVIORAL; Name: Early intervention blending several tx approaches, w/ focus; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Early intervention blending several treatment approaches; Assigned to Arm(s): 2
D: Intervention Type: BEHAVIORAL; Name: Joint attention intervention; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Aripiprazole Monotherapy in the Treatment of Acutely Manic Patients With Bipolar I Disorder
Brief Summary: The purpose of this trial is to test the safety \& efficacy of aripiprazole in patients with Bipolar Mania for a period of at least 12 weeks.


Options:
A: Intervention Type: DRUG; Name: Seroquel (quetiapine); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): N/A
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: aripiprazole | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B
D: Arm Label: Participants will take aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Participants will take risperidone; Type: EXPERIMENTAL; Interventions: Drug: Risperidone | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Participants will take aripiprazole | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Participants will take risperidone

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind Study on the Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder
Brief Summary: The primary purpose of this study is to compare the affects of aripiprazole and olanzapine on weight change.


Options:
A: Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A
B: Arm Label: 1. Paliperidone ER; Type: EXPERIMENTAL; Interventions: Drug: Paliperidone ER | Arm Label: 2 Risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Intervention Type: DRUG; Name: Paliperidone ER; Assigned to Arm(s): 1. Paliperidone ER | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): 2 Risperidone
C: Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Phase II Proof-of-Concept Study to Evaluate the Safety and Efficacy of a 3-Dose Regimen of the Merck Adenovirus Serotype 5 HIV-1 Gag/Pol/Nef Vaccine (MRK AD5 HIV-1 Gag/Pol/Nef) in Adults at High Risk of HIV-1 Infection
Brief Summary: This study will test the safety and efficacy of an investigational Human Immunodeficiency Virus (HIV) vaccine. Efficacy will be measured by either prevention of HIV infection or control of HIV viral load in subjects who become HIV infected.

On September 18, 2007 the Protocol V520-023 DSMB (Data \& Safety Monitoring Board) reviewed data from a planned interim analysis. These data demonstrated that the investigational vaccine candidate was not effective, and all vaccinations in the study were halted.

Participants were encouraged to continue to come to the clinic for scheduled visits and ongoing risk reduction counseling since the vaccine was not effective.


Options:
A: Intervention Type: DRUG; Name: Acyclovir (ACV); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: acyclovir; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Acyclovir | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Acyclovir placebo | Intervention Type: DRUG; Name: Acyclovir; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Acyclovir placebo; Assigned to Arm(s): 2
D: Arm Label: Trivalent MRKAd5 HIV-1 gag/pol/nef; Type: EXPERIMENTAL; Interventions: Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 ad-vg/dose) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: placebo | Intervention Type: BIOLOGICAL; Name: Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 ad-vg/dose); Assigned to Arm(s): Trivalent MRKAd5 HIV-1 gag/pol/nef | Intervention Type: DRUG; Name: Comparator: placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) Trial
Brief Summary: The purpose of this study is to determine if ramipril and/or rosiglitazone prevent the onset of type 2 diabetes.


Options:
A: Arm Label: Rosuvastatin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Rosuvastatin | Arm Label: Candesartan/HCT; Type: PLACEBO_COMPARATOR; Interventions: Drug: Candesartan/HCT | Intervention Type: DRUG; Name: Candesartan/HCT; Assigned to Arm(s): Candesartan/HCT | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Olmesartan medoxomil | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Tablets | Intervention Type: DRUG; Name: Olmesartan medoxomil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo Tablets; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Combination of Telmisartan and Ramipril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) Trial
Brief Summary: The purpose of this study is to determine if ramipril and/or rosiglitazone prevent the onset of type 2 diabetes.


Options:
A: Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): N/A
B: Arm Label: Valsartan 160 mg + nateglinide 60 mg; Type: EXPERIMENTAL; Interventions: Drug: Valsartan 160 mg + nateglinide 60 mg | Arm Label: Valsartan 160 mg + nateglinide placebo; Type: EXPERIMENTAL; Interventions: Drug: Valsartan 160 mg + nateglinide placebo | Arm Label: Nateglinide 60 mg + valsartan placebo; Type: EXPERIMENTAL; Interventions: Drug: Nateglinide 60 mg + valsartan placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Valsartan placebo + nateglinide placebo | Intervention Type: DRUG; Name: Valsartan 160 mg + nateglinide 60 mg; Assigned to Arm(s): Valsartan 160 mg + nateglinide 60 mg | Intervention Type: DRUG; Name: Valsartan 160 mg + nateglinide placebo; Assigned to Arm(s): Valsartan 160 mg + nateglinide placebo | Intervention Type: DRUG; Name: Nateglinide 60 mg + valsartan placebo; Assigned to Arm(s): Nateglinide 60 mg + valsartan placebo | Intervention Type: DRUG; Name: Valsartan placebo + nateglinide placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Indapamide SR 1.5mg; Perindopril 2-4mg; Assigned to Arm(s): N/A
D: Arm Label: Rosuvastatin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Rosuvastatin | Arm Label: Candesartan/HCT; Type: PLACEBO_COMPARATOR; Interventions: Drug: Candesartan/HCT | Intervention Type: DRUG; Name: Candesartan/HCT; Assigned to Arm(s): Candesartan/HCT | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) Trial
Brief Summary: The purpose of this study is to determine if ramipril and/or rosiglitazone prevent the onset of type 2 diabetes.


Options:
A: Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): N/A
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Pioglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pioglitazone | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Pioglitazone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1 Original Lifestyle; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: DPPOS Boost Lifestyle, Behavioral: Intensive Lifestyle Group Session | Arm Label: 2 Original Metformin; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Drug: Metformin, Behavioral: Intensive Lifestyle Group Session | Arm Label: 3 Original Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: Intensive Lifestyle Group Session | Intervention Type: BEHAVIORAL; Name: DPPOS Group Lifestyle; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 2 Original Metformin | Intervention Type: BEHAVIORAL; Name: DPPOS Boost Lifestyle; Assigned to Arm(s): 1 Original Lifestyle | Intervention Type: BEHAVIORAL; Name: Intensive Lifestyle Group Session; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo
D: Arm Label: Valsartan 160 mg + nateglinide 60 mg; Type: EXPERIMENTAL; Interventions: Drug: Valsartan 160 mg + nateglinide 60 mg | Arm Label: Valsartan 160 mg + nateglinide placebo; Type: EXPERIMENTAL; Interventions: Drug: Valsartan 160 mg + nateglinide placebo | Arm Label: Nateglinide 60 mg + valsartan placebo; Type: EXPERIMENTAL; Interventions: Drug: Nateglinide 60 mg + valsartan placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Valsartan placebo + nateglinide placebo | Intervention Type: DRUG; Name: Valsartan 160 mg + nateglinide 60 mg; Assigned to Arm(s): Valsartan 160 mg + nateglinide 60 mg | Intervention Type: DRUG; Name: Valsartan 160 mg + nateglinide placebo; Assigned to Arm(s): Valsartan 160 mg + nateglinide placebo | Intervention Type: DRUG; Name: Nateglinide 60 mg + valsartan placebo; Assigned to Arm(s): Nateglinide 60 mg + valsartan placebo | Intervention Type: DRUG; Name: Valsartan placebo + nateglinide placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Aripiprazole as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder.
Brief Summary: This trial is a 14 week, randomized, double-blind, placebo controlled study, to assess the safety and efficacy of aripiprazole as adjunctive treatment to an ongoing antidepressant treatment in patients with Major Depressive Disorder.


Options:
A: Arm Label: A1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Antidepressant + Placebo | Arm Label: A2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Antidepressant + Aripiprazole | Arm Label: A3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Antidepressant + Placebo; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Antidepressant + Aripiprazole; Assigned to Arm(s): A2
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lamotrigine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Amide | Intervention Type: DRUG; Name: Lamotrigine; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Amide; Assigned to Arm(s): 2
C: Arm Label: Drug 2mg/Drug 5mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole 5mg, Drug: Aripiprazole 2mg | Arm Label: Placebo/Drug 2mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole 2mg, Drug: Placebo | Arm Label: Placebo/Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aripiprazole 5mg; Assigned to Arm(s): Drug 2mg/Drug 5mg | Intervention Type: DRUG; Name: Aripiprazole 2mg; Assigned to Arm(s): Drug 2mg/Drug 5mg, Placebo/Drug 2mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Drug 2mg, Placebo/Placebo
D: Arm Label: Vilazodone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vilazodone | Arm Label: Citalopram; Type: PLACEBO_COMPARATOR; Interventions: Drug: Citalopram | Intervention Type: DRUG; Name: Vilazodone; Assigned to Arm(s): Vilazodone | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): Citalopram

Answer: A